ZYCUBO (Copper Histidinate) Patent Expiration, LOE Window & CMS Spending

ZYCUBO (Copper Histidinate) by Sentynl Therapeutics: FDA Orange Book LOE 2033-01-12, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,867 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSentynl Therapeutics
FDA Application & PathwayN211241 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-01-12
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,867 intro WAC)